Chitosan microparticles for mucosal vaccination against diphtheria: Oral and nasal efficacy studies in mice

Vaccine

Volumn 21, Issue 13-14, 2003, Pages 1400-1408

  Van Der Lubben, Inez M ^a   Kersten, Gideon ^b   Fretz, Marjan M ^a   Beuvery, Coen ^b   Verhoef, J Coos ^a   Junginger, Hans E ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Chitosan microparticles; Diphtheria toxoid (DT); Mucosal immune response (IgA); Nasal vaccination; Oral vaccination; Systemic immune response (IgG)

Indexed keywords

ALUMINUM HYDROXIDE; CHITOSAN; DIPHTHERIA VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY PRODUCING CELL; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIPHTHERIA; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; NOSE MUCUS; PRIORITY JOURNAL; VACCINATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; CHITIN; CHITOSAN; DIPHTHERIA TOXOID; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; VACCINATION;

EID: 0037471396     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00686-2     Document Type: Article

References (31)

1. Lydyard P, Grossi C. The lymphoid system. In: Roitt I, Brostoff J, Male, D. editors. Immunology. London: Mosby; 1998. p. 31-42.
2. Alpar H.O., Ward K.R., Williamson E.D. New strategies in vaccine delivery. S.T.P. Pharma Sci. 10:2000;269-278.
3. Van der Lubben I.M., Konings F.A.J., Borchard G., Verhoef J.C., Junginger H.E. In vivo uptake of chitosan microparticles by murine Peyer's patches: visualization studies using confocal laser scanning microscopy and immunohistochemistry. J. Drug Target. 9:2001;39-47.
4. Barackman J.D., Singh M., Ugozolli M., Ott G.S., O'Hagan D.T. Oral immunization with poly(lactide-co-glycolide) microparticles containing an entrapped recombinant glycoprotein (gD2) from Herpes simplex type 2 virus. STP Pharma Sci. 8:1998;41-46.
5. Igartua M., Hernandez R.M., Esquisabel A., Gascon A.R., Calvo M.B., Pedraz J.L. Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. J. Control. Rel. 56:1998;63-73.
6. Cho N.-H., Seong S.-Y., Chun K.-H., Kim Y.-H., Kwon I., Ahn B.-Y.et al. Novel mucosal immunization with polysaccharide-protein conjugates entrapped in alginate microspheres. J. Control. Rel. 53:1998;215-224.
7. Heritage P.L., Underdown B.J., Brook M.A., Mc Dermott M.R. Oral administration of polymer-grafted starch microparticles activates gut-associated lymphocytes and primes mice for a subsequent systemic antigen challenge. Vaccine. 16:1998;2010-2017.
8. Eldridge J.H., Hammond C.J., Meulbroek J.A., Staas J.K., Gilley R.M., Rice T.R. Controlled vaccine release in the gut associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J. Control. Rel. 11:1990;205-214.
9. Kuper C.F., Koornstra P.J., Hameleers D.M.H., Biewenga J., Spit B.J., Duijvestijn A.M.et al. The role of nasopharyngeal lymphoid tissue. Immunol. Today. 13:1992;219-224.
10. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 15:1998;1326-1331.
11. Eyles J., Sharp G., Williamson E., Spiers I., Alpar H. Intranasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine. 16:1998;698-707.
12. Challacombe S., Rahman D., O'Hagan D. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine. 15:2000;169-175.
13. Kim S.Y., Doh H.J., Ahn J.S., Ha Y.J., Jang M.H., Chung S.I.et al. Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly(D, L-lactide-co-glycolide) microparticles. Vaccine. 17:1999;607-616.
14. Alpar H.O., Eyles J., Williamson E. Oral and nasal immunization with microencapsulated clinically relevant proteins. STP Pharma Sci. 8:1998;31-39.
15. Calvo P., Remunan-Lopez C., Vila-Jato J.L., Alonso M.J. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polym. Sci. 63:1997;125-132.
16. Van der Lubben I.M., Verhoef J.C., Van Aelst A., Borchard G., Junginger H.E. Chitosan microparticles for oral vaccination: preparation, characterisation and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials. 22:2001;687-694.
17. Jabbal-Gill I., Fischer A.N., Rappuoli R., Davis S.S., Illum L. Stimulation of mucosal and systemic responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine. 16:1998;2039-2046.
18. McNeela E.A., O'Connor D., Jabbal-Gill I., Illum L., Davis S.S., Pizza M.et al. A mucosal vaccine against diphtheria: formulation of cross-reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine. 19:2001;1188-1198.
19. Lowry O, Rosebrough N. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193-265.
20. Elson C.O., Ealding W., Lefkowitz J. A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions. J. Immunol. Methods. 67:1986;101-108.
21. Gizurarson S. Animal models for intranasal drug delivery studies. Acta Pharm. Nord. 2:1990;105-122.
22. Kreeftenberg J.G., Van der Gun J., Marsman F.R., Sekhuis V.M., Bhandari S.K., Maheshwari S.C. An investigation of a mouse model to estimate the potency of diphtheria component in vaccines. J. Biol. Stand. 13:1985;229-234.
23. Frech C., Hilbert A.K., Hartmann G., Mayer K., Sauer T., Bolgiano B. Physicochemical analysis of purified diphtheria toxoids: is toxoided then purified the same as purified then toxoided? Dev. Biol. 103:2001;205-215.
24. Gupta R.K., Siber G.R. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine. 13:1995;1263-1276.
25. Rinella J.V., White J.L., Hem S.L. Treatment of aluminium hydroxide adjuvant to optimize the adsorption of basic proteins. Vaccine. 14:1996;298-300.
26. Shi Y., HogenEsch H., Hem S.L. Change in the degree of adsorption of proteins by aluminium-containing adjuvants following exposure to interstitial fluid: freshly prepared and aged model vaccines. Vaccine. 20:2002;80-85.
27. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol. 148:1987;265-276.
28. Bjorkholm B., Bottiger M., Christenson B., Hagberg L. Antitoxin antibody levels and the outcome of illness during an outbreak of diphtheria among alcoholics. Vaccine. 19:2001;167-173.
29. Bacon A., Makin J., Sizer P.J., Jabbal-Gill I., Hinchcliffe M., Illum L.et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect. Immun. 68:2000;5764-5770.
30. Aiba S. Studies on chitosan. 4. Lysozymic hydrolysis of partially N-acetylated chitosans. Macromolecules. 14:1992;225-228.
31. Van der Lubben I.M., Verhoef J.C., Borchard G., Junginger H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. 14:2001;201-207.